Heart Failure | Disease Landscape and Forecast | G7 | 2024
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and chronic heart failure (CHF) have distinct treatment pathways, and both are covered in this report. The use of sacubitril / valsartan and SGLT-2 inhibitors is expanding for CHF. Despite the availability of these treatments, substantial unmet needs remain in the treatment of CHF. The CHF therapy market will expand over the 2023-2033 forecast period, fueled by the continued uptake of branded therapies, including the launch of new drugs addressing unmet needs and the increase in HF prevalence over the forecast period. We expect several therapies to launch for heart failure with preserved ejection fraction (HFpEF) during the forecast period, including Bayer’s finerenone, Eli Lilly’s tirzepatide, Novo Nordisk’s semaglutide 2.4 mg and ziltivekimab, Boehringer Ingelheim’s vicadrostat, and AstraZeneca’s balcinrenone / dapagliflozin FDC.
QUESTIONS ANSWERED
- What are the incidence of AHF events and the prevalence of CHF cases in the major pharmaceutical markets under study?
- What are the drivers and constraints in the heart failure therapy market, and how will the market evolve through 2033?
- What are the greatest unmet needs in the treatment of heart failure? Which drugs in development will fulfill these unmet needs?
- How will the treatment of HFpEF evolve following the launch of novel therapies for this population?
- Which emerging therapies generate the most enthusiasm among thought leaders, and what is the expected level of market penetration of these agents?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 27 country-specific interviews with thought-leading cardiologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction
- Drug treatments: Coverage of key current and emerging therapies.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key HF therapies through 2033, segmented by brands / generics, country, and ejection fraction
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
KEY FEATURES
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
